Kimberley S. Mak, MD, MPH, is an Assistant Professor of Radiation Oncology at the Boston University School of Medicine and its affiliate Boston Medical Center. She received her MPH from Harvard School of Public Health (2014), MD from Harvard Medical School (2010) and AB summa cum laude in Biochemical Sciences from Harvard College (2005). Dr. Mak completed an internship in Internal Medicine at Brigham and Women’s Hospital (2011), followed by residency in the Harvard Radiation Oncology Program (2015), training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children’s Hospital of Boston, and Boston Medical Center. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology. She speaks English and Cantonese. Her specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies.
Her research interests include patient-reported outcomes including quality of life; disparity outcomes research; translational research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work.
- Boston Medical Center
- Member, BU-BMC Cancer Center, Boston University
- VA Boston Healthcare System
- Harvard Medical School, MD
- Harvard School of Public Health, MPH
- Harvard College, AB
- Published on 9/16/2020
Moeller AR, Clancy PE, Qureshi MM, Guill JR, Dyer MA, Hirsch AE, Truong MT, Mak KS. Placard in Hand: A Simple, Inexpensive Intervention to Improve On-Treatment Visit Compliance in a Safety Net Radiation Oncology Patient Population. JCO Oncol Pract. 2020 Nov; 16(11):e1272-e1281. PMID: 32936711.
- Published on 6/10/2020
Yu S, Xu H, Sinclair A, Zhang X, Langner U, Mak K. Dosimetric and planning efficiency comparison for lung SBRT: CyberKnife vs VMAT vs knowledge-based VMAT. Med Dosim. 2020 Winter; 45(4):346-351. PMID: 32532613.
- Published on 3/9/2020
Shah NK, Qureshi MM, Dyer MA, Truong MT, Mak KS. Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival. J Gastrointest Cancer. 2020 Mar 09. PMID: 32152823.
- Published on 12/19/2019
Asokan S, Sridhar P, Qureshi MM, Bhatt M, Truong MT, Suzuki K, Mak KS, Litle VR. Presentation, Treatment, and Outcomes of Vulnerable Populations With Esophageal Cancer Treated at a Safety-Net Hospital. Semin Thorac Cardiovasc Surg. 2020 Summer; 32(2):347-354. PMID: 31866573.
- Published on 4/1/2019
Yan SX, Qureshi MM, Dyer M, Truong MT, Mak KS. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer. Lung Cancer. 2019 05; 131:147-153. PMID: 31027693.
- Published on 12/31/2018
Sridhar P, Bhatt M, Qureshi MM, Asokan S, Truong MT, Suzuki K, Mak KS, Litle VR. Esophageal Cancer Presentation, Treatment, and Outcomes Vary With Hospital Safety-Net Burden. Ann Thorac Surg. 2019 05; 107(5):1472-1479. PMID: 30605641.
- Published on 7/24/2018
Yan SX, Qureshi MM, Suzuki K, Dyer M, Truong MT, Litle V, Mak KS. Definitive treatment patterns and survival in stage II non-small cell lung cancer. Lung Cancer. 2018 10; 124:135-142. PMID: 30268452.
- Published on 8/29/2017
Mak KS, Lee SW, Balboni TA, Marcus KJ. Clinical outcomes and toxicity following palliative radiotherapy for childhood cancers. Pediatr Blood Cancer. 2018 Jan; 65(1). PMID: 28853208.
- Published on 8/21/2017
Giacalone NJ, Qureshi MM, Mak KS, Kirke D, Patel SA, Shah BA, Salama AR, Jalisi S, Truong MT. Adjuvant chemoradiation does not improve survival in elderly patients with high-risk resected head and neck cancer. Laryngoscope. 2018 04; 128(4):831-840. PMID: 28833217.
- Published on 6/1/2017
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017 Jun 01; 3(6):827-831. PMID: 27892978.
View 17 more publications: View full profile at BUMC